Co-founded by Dr. Marco Colonna, a global expert in neuroimmunology and Alzheimer’s research Led by CEO Gabriella Camboni, an eminent serial entrepreneur with a track record of successful biotech ventures MILAN, Italy – March 18, 2025 – BioClec, a cutting-edge biotechnology company focused on breakthrough therapies for Alzheimer’s disease (AD), announces its launch today. Emerging […]
Signadori Bio, a novel cell therapy platform, emerges from collaboration with scientific founders Dr. Jean-Luc Perfettini and Professor Nathalie Chaput PARIS, France – March 18, 2025 — Sofinnova Partners, a leading European life sciences venture capital firm, in collaboration with Gustave Roussy, Europe’s leading cancer center, announces the creation of their first pioneering biotech company. […]
Biovelocita II attracts robust support from leading pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures The fund has already screened over 300 projects and made several investments into new companies to catalyze transformative innovation in biotechnology PARIS, France – March 18, 2025 – Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital […]
Leading European venture capital firm exceeds €4 billion in assets under management, doubling its AUM in the last five years PARIS, France – March 4, 2025 — Sofinnova Partners (“Sofinnova”), a leading European venture capital firm in life sciences based in Paris, London, and Milan, today announced it had raised €1.2 billion across its platform […]
Our clients finished off January on a positive note, with some great investment news from Commit, a fundraising milestone from the Novo Nordisk Foundation, and breakthrough AI results from BrightHeart. Novo Nordisk Foundation granted DKK 10 billion (€1.35 billion) to benefit people and the planet in milestone year Following its 100th anniversary in 2024, the […]
